Ant i body (generation)

Antibody Specificity

rituximab)

Additional Features

Type

Isotype

CDR

CDC

ADCC

Apoptosis

(compared to rituximab)

Clinical Trials*

References

Tositumomab

Ost)

II

lgG2A

Murine

—

=

+ +

Bound to radioisotopes

Bound to

radioisotopes: NHL

9, 73, 75

Ofatumumab

(2nd)

I

IgGI

Humań

+ + +

-    Binds the smali extracellular part of CD20

-    Completely human

-    Slower off-rate

Phase l/ll: RA, FL, CLL, WM, RRMS Phase III: CLL, FL, DLBCL

10, 76-83

Ocrelizumab

(2nd)

I

IgGI

Humanized

=/+

Binds a different but overlapping epitope compared to rituximab

Phase 1, II, III: RA NHL Phase III: SLE Phase II: RRMS

69,91,92

Veltuzumab

(2nd)

I

IgGI

Humanized

=/+

Slower off-rate

Phase l/ll: CLL, NHL, ITP

84-90

PROI BI 921

I

lgG1

Humanized

=

++

=

Enhanced affinity for FcyRII

Phase l/ll: CLL, NHL

93, 94

(3rd)

AME-1 33

I

lgG1

Humanized

=

+

=

Enhanced affinity for CD20

Phase l/ll: NHL

95, 96

(3rd)

GAI 01 (Brd)

II

IgGI

Humanized

+++

+++

-    High affinity for FcyRII

-    Strong induction of apoptosis

Phase l/ll: NHL

99-112